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Summary 
We documented a high prevalence of pretreatment drug resistance (PDR) amongst participants enrolled in trial 
clinics in rural KwaZulu-Natal. Dual class PDR to first-line tenofovir/emtricitabine/efavirenz regimen was 
associated with poorer VS. However, there was no impact of NNRTI PDR alone. 
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Abstract 
Background  
Previous studies in HIV-positive individuals on thymidine analogue backbone antiretroviral therapy (ART) with 
either nevirapine or efavirenz have suggested poorer virological outcomes in the presence of pretreatment drug 
resistance (PDR).  We assessed the impact of PDR on virological suppression (VS) [<50copies/mL] in 
individuals prescribed primarily tenofovir/emtricitabine/efavirenz in rural KwaZulu-Natal within a Treatment as 
Prevention trial.  
 
Methods  
Among 1,557 HIV-positive individuals reporting no prior ART at study entry and provided plasma samples, 
1,328 individuals with entry viral load (VL) >1,000 copies/mL had next generation sequencing (NGS) of the 
HIV pol gene with MiSeq technology. Results were obtained for 1,148 individuals and the presence of PDR 
assessed at 5% and 20% detection thresholds. Virological outcome was assessed using Cox regression in 837 of 
920 ART initiators with at least one follow-up VL after ART initiation. 
Results 
PDR prevalence was 9.5% (109/1,148) and 12.8% (147/1,148) at 20% and 5% thresholds respectively. After a 
median of 1.36years (IQR 0.91-2.13), mostly on fixed-dose combination (FDC) 
tenofovir/emtricitabine/efavirenz, presence of both NRTI/NNRTI PDR vs. no PDR was associated with longer 
time to VS [aHR 0.32, 95%CI=0.12-0.86] while there was no difference between those with only NNRTI PDR 
vs. no PDR [aHR 1.05, 95%CI=0.82-1.34] at the 5% threshold. Similar differences were observed for mutations 
detected at the 20% threshold, although without statistical significance. 
Conclusions  
NGS uncovered a high prevalence of PDR amongst participants enrolled in trial clinics in rural KwaZulu-Natal. 
Dual class PDR to a mainly tenofovir/emtricitabine/efavirenz was associated with poorer VS. However, there 
was no impact of NNRTI PDR alone. 
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Introduction  
HIV antiretroviral therapy (ART) scale-up in Eastern and Southern Africa has been a great success, with a 
doubling of the number of people on ART since 2010, reaching 10.3 million people in 2016 with a 36% decline 
in the number of AIDS-related deaths [1]. Despite the benefits of ART for individuals and populations [2, 3], 
expanding ART access and longer time on therapy might increase emergence and transmission of drug 
resistance (DR)  [4], which could potentially compromise public ART programmes in settings using 
standardized first-line regimens. The majority of studies in SSA (Supplementary Table 1) have shown a 
detrimental impact of pre-treatment DR (PDR) on virological outcomes in individuals prescribed first-line ART 
mainly comprising a thymidine analogue backbone (zidovudine [ZDV] or stavudine [d4T] combined with either 
efavirenz (EFV) or nevirapine (NVP) [4-9]. Four of these studies accounted for ART adherence [4-6, 8]. Fewer, 
generally  smaller sized studies, studying populations  prescribed mainly older first-line ART regimen, have not 
shown a similar association [10-13].  
 
Within the Treatment as Prevention (TasP) trial, a cluster-randomised trial undertaken in an HIV hyper-
epidemic setting in rural KwaZulu-Natal, South Africa [14], we estimated the prevalence of PDR using next 
generation sequencing (NGS) technologies amongst HIV-positive participants who reported not to be on ART at 
entry into trial clinics. We evaluated the association between PDR, and response to first-line ART 
(predominantly fixed-dose combination (FDC) tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) (Atripla®)) 
in individuals who initiated ART within the trial. 
 
Methods 
Ethics statement 
The trial was approved by the Biomedical Research Ethics Committee (BFC 104/11) at the University 
of KwaZulu-Natal and the Medicines Control Council of South Africa (Clinicatrials.gov: NCT01509508; South 
African National Clinical Trials Register: DOH-27-0512-3974). All trial participants gave written or witnessed 
thumbprint informed consent prior to undertaking any study procedures. 
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Study Design and Trial Setting 
The ANRS 12249 TasP trial was implemented in the Hlabisa sub-district in rural KwaZulu-Natal [14], one of 
the poorest communities in South Africa, with high unemployment rate [15]. This was a cluster-randomised trial 
undertaken between March 2012 and June 2016 in 22 clusters (2 x11) [16, 17]; participants residing in the 
intervention clusters were offered ART after HIV diagnosis, regardless of their CD4 count, whereas participants 
in control clusters were offered ART according to the prevailing South African guidelines.  
 
Study Procedures and Laboratory Methods 
Individuals 16 years and above testing HIV-positive through home-based rapid test or who self-reported to be 
HIV-positive were referred to the trial clinics in their cluster, regardless of their ART status.  
Individuals who linked to care were asked to complete study questionnaires and provide plasma samples at their 
first trial clinic visit, then at three months, six months and six monthly thereafter, if they initiated ART. Plasma 
samples were used for viral load (VL) testing, using the Abbott RealTime HIV-1 m2000rt (Abbott Molecular 
Inc, Des Plaines, IL, USA), as well as for DR testing in the Africa Health Research Institute diagnostic 
laboratory. Individuals visited the clinics monthly for their ART prescription, where adherence was measured 
using the visual analogue scale (VAS) [18]. Participants were asked to mark their level of adherence in the 
previous 4 days on a visual analogue scale ranging from 0 (no ART tablets taken) to 100% (all ART tablets 
taken). Adherence was suboptimal if ≤95%. 
 
Plasma samples with VL≥1,000 copies/mL were characterised for HIV pol with NGS, using MiSeq technology, 
according to an adapted protocol from Gall et al (Supplementary Methods 1 and Supplementary Table 2) [19]. 
After reads assemblies using Geneious 10.0.6 software [20] and quality control of NGS data, DR mutations 
(DRM) were called at a threshold of 5% (Supplementary Methods 2). Resistant variants were included in the 
analysis when they were also detected by another application available in BaseSpace MiCall [21]. The DRM 
were documented using the WHO 2009 surveillance of DRM [22]; PDR prevalence and impact were estimated 
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from DRM detected at >5%, confidence level of real mutation detection, and >20%, level of detection reached 
by Sanger population sequencing, most common technique used in DR testing.  
 
Statistical Analysis 
The characteristics of individuals who had NGS sequence data at baseline with and without PDR were 
tabulated. Characteristics of individuals who initiated ART in the trial, had NGS sequence data at baseline, and 
had at least one follow-up VL measurement (i.e. so included in the analysis of VS) were tabulated and compared 
with those of individuals who were missing VL at follow-up. We checked for completeness of VL 
measurements in those with and without PDR during the first 12 months after ART initiation to exclude 
ascertainment bias. 
Categorical variables were summarised using frequencies and proportions, and compared using Chi-squared 
tests. Continuous variables were summarised using median and interquartile ranges (IQR), and compared using 
Mann-Whitney tests.  
We computed the overall proportions of individuals with any PDR and NNRTI at 5% and 20% detection 
thresholds. We examined the association between PDR stratified based on predicted response to the 
antiretroviral drugs prescribed (no PDR, only NNRTI PDR or both NRTI/NNRTI PDR), and time to VS. Two 
separate analyses were undertaken for time to VS; PDR was defined as whether or not mutations were present at 
the 20% threshold, and then at the 5% threshold. Kaplan Meier methods were used to estimate time to VS in the 
three PDR categories, which were compared using the log rank test. Individuals entered the analysis at the date 
of ART initiation; those who did not achieve VS were censored at the date of their last VL measurement. Cox 
regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of 
PDR and other factors with VS. Factors that were associated with VS at p<0.15 in the unadjusted analysis were 
included in a multivariable model; age and sex were retained a priori as potential confounders. CD4 count and 
age were included in the model as continuous covariates. In order to allow for a non-linear relationship between 
CD4 count, age and time to VS, we used fractional polynomial functions which provide a flexible way to model 
the shape of the relationship of a continuous variable with the outcome [23]. We used a set of defined powers (–
2, –1, –0.5, 0.5, 1, 2 and ln(x)) and a maximum of two power terms in the model. The differences in model 
deviances were compared; the linear model was used if the improvement in fit was not statistically significant at 
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p<0.05. Mean VAS adherence during follow-up was calculated by taking the average adherence in the visits 
prior to achieving VS in those that suppressed or the average adherence in the visits prior to censoring in those 
that did not achieve VS. Missing adherence measurements were omitted. VAS adherence was transformed into a 
categorical variable using clinically meaningful cut-offs. VL was handled in a similar manner. 
After fitting the full model, the proportional hazard assumption was tested both globally and for individual 
covariates, by regressing the scaled Schoenfeld residuals on time; the null hypothesis was that the slope was 
zero, i.e. that the log HR function was constant over time.  
 
Results  
Cohort description  
Of the 1,557 participants who reported not to be on ART at entry, 1,328 (85.3%) had a VL>1,000 copies/mL of 
whom 1,148 (86.4%) had successful NGS of the HIV pol gene (consensus sequences available in GenBank, 
accession numbers: MH709380 – MH710527). Of the 1,148 with NGS data, 920 (80.1%) initiated ART within 
the trial of whom 837 individuals had at least one VL result after ART initiation (Figure 1). 
 
Prevalence of any PDR or NNRTI DRM 
Of the 1,148 participants who had their virus successfully sequenced, 109 (9.5%) had at least one PDR mutation 
detected at 20% threshold, NNRTI resistance being predominant with a prevalence of 101/1,148 (8.8%). The 
number of participants with any PDR mutation increased to 147 (12.8%) when minority variants were accounted 
for at 5% threshold (Figure 2). Prevalence of NRTI resistance was low with 12 (1.1%), and 23 (2.0%) 
participants out of 1,148 having NRTI DRM detected at 20% and 5% thresholds, while protease inhibitor 
resistance was found in 8 (0.7%) and 16 (1.4%) individuals respectively. Detailed description of the DRM are 
presented in Supplementary Figure 1 and Supplementary Figure 2. 
 
Amongst those with resistance, dual class NRTI/NNRTI DRM were found in 6/109 (5.5%) and 11/147 (7.8%) 
participants with PDR at 20% and 5% thresholds respectively (Supplementary Table 3). 
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The majority of participants with virus sequences had a median age of 32.9 years (IQR 25.6-45.2), with 
characteristics described in Table 1. The median CD4 count at clinic presentation was 405cells/mm
3 
(IQR 261-
559) and the median VL was 4.5log10 copies/mL (IQR 3.9-5.2). There was no difference in the median age of 
individuals with sequences (n=1,148) and those without (n=409; 32.9 years (IQR 25.6-45.2) vs. 33.5 years (IQR 
26.6-45.6), p=0.67]. A higher proportion of female than men had no virus sequences (28.1% vs. 21.4%, 
p=0.008). 
 
Association of pre-treatment drug resistance with virologic suppression.  
Of the 920 individuals who initiated ART (96.3% started Atripla®) and had virus sequence data, 837 had at 
least one follow-up VL and were used to examine the impact of PDR on response to therapy. There was no 
statistically significant difference in the completeness of VL measurements at each visit between individuals 
with and without PDR during the first 12 months of ART (Supplementary Table 4). Their median age was 34.3 
years, 72% were female, and 83.5% had an overall mean VAS adherence ≥95% (Table 2). The 83 participants 
with missing VL data were younger than those with VL data [median age 29.5 years (IQR 23.5-41.6) vs. 
34.3years (27.3-46.5); p=0.02] and a higher proportion were male (42% vs. 28%; p=0.009). The prevalence of 
any PDR at the 20% threshold in participants with and without VL data (9.4% vs 12.1%; p=0.44, respectively) 
was similar to that in all individuals with sequences (9.5%).  
 
Amongst the 837 HIV-positive individuals who contributed to the analysis; 748 individuals had no PDR, 82 had 
NNRTI PDR only and 7 had both NRTI and NNRTI PDR at the 5% threshold. At the 20% threshold, the 
corresponding numbers were 765, 67 and 5 respectively. Participants were followed for a median of 1.36years 
(IQR 0.91-2.13) after ART initiation. At the 20% detection threshold, time to VS was longer for those with both 
NRTI/NNRTI  PDR than those without any PDR [median 11.73months (IQR 2.76-16.39) vs. 3.45months (IQR 
2.79-5.75)], whilst there was no significant difference between those with only NNRTI PDR compared to those 
with no PDR [median 4.11months (IQR 2.86-5.98) vs. 3.45months (IQR 2.79-5.75)]  (Figure 3a) (log rank test 
overall; p=0.10) At the 5% detection threshold, time to VS was longer for those with both NRTI/NNRTI  PDR 
than those without any PDR [median 11.73 months (IQR 2.76-16.39) vs. 3.48months (IQR 2.79-5.78)], whilst 
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there was no difference between those with only NNRTI PDR compared to those with no PDR [ median 
3.71months (IQR 2.79-5.55) vs. 3.48months (IQR 2.79-5.78)]  (Figure 3b) (log rank test overall; p=0.09) The 
median time to achieve VS, overall, was 3.61months (IQR 2.79-5.78). The overall cumulative probability of VS 
at 12 months was 94.5% (95% CI 92.7-96.0).  
 
In unadjusted Cox models, for resistant variants detected at 20% (Table 3), there was an association between 
presence of both NRTI/NNRTI PDR with longer time to VS but this did not reach statistical significance (HR 
0.42 (95% CI 0.16-1.12). However, there was no association with VS for those with only NNRTI PDR (HR 
0.84 (0.64-1.11). Factors associated with longer time to VS were being male and having a high VL at baseline 
(>100,000 copies/mL), while a mean VAS adherence of ≥95% and a higher CD4 count at initiation were 
associated with shorter time to VS. In a multivariable Cox regression model that adjusted for age, sex, CD4 
count and VL at ART initiation, and adherence, the association between having both NRTI/NNRTI PDR and 
VS remained virtually unchanged from the unadjusted model [adjusted (a)HR 0.41, 95%CI=0.15-1.10] with 
attenuation of the effect of association between having only NNRTI PDR and VS [aHR 0.90 (0.68-1.18)]. 
Having a high baseline VL was independently associated with significantly longer time to VS while VAS 
adherence ≥95% remained independently associated with shorter time to VS.  
When we repeated the analysis taking into account the presence of resistant variants detected at the 5% 
threshold (Table 4), we found a statistically significant association between having both NRTI/NNRTI PDR and 
longer time to VS [both NRTI/NNRTI PDR vs. no PDR; aHR 0.32, 95%CI=0.12-0.86]. There was no difference 
in time to VS between having only NNRTI PDR and no PDR [aHR 1.05, 95%CI=0.82-1.34] 
 
Discussion  
We report the first study from the sub-Saharan HIV epidemic exploring NGS-defined DR, and response to 
currently recommended first-line FDC therapy. The prevalence of any PDR was 9.5% at 20% detection level, 
and up to 13% with a detection limit of 5% amongst HIV-positive individuals reporting no prior ART at entry 
into the trial. Virological response was similar between individuals who had only NNRTI PDR and those who 
had no PDR. However, VS was poorer in individuals who had dual-class NRTI/NNRTI PDR than in those 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy881/5130579 by Sussex U
niversity user on 25 O
ctober 2018
  12 
without PDR at the 5% threshold. The association at the 20% threshold did not reach statistical significance 
most likely due to very small numbers of individuals with dual-class PDR. 
 
Our findings contrast with two large cohort studies addressing a similar question in SSA, in which PDR defined 
by population sequencing was associated with virological failure or treatment switch when at least one drug was 
compromised in participants initiating first-line ART [4, 5]. The majority of participants in the cited studies 
were on AZT or d4T backbone in combination with either NVP or EFV. By contrast, only a third of the 
participants in these two studies were on TDF with either 3TC or FTC combined with NVP or EFV.  Other 
similar studies in individuals prescribed predominantly older ART regimen have also shown an association 
between poorer virological response and PDR when at least one drug was compromised [6-8]. In our study with 
NGS-defined PDR, nearly all participants were on fixed dose combination TDF/FTC/EFV with VS being 
compromised only when PDR to at least two of the prescribed drugs was present. There was no difference in VS 
between patients with only NNRTI PDR and those with no PDR, a finding collaborated by a descriptive study 
which showed that virological response was similar in individuals with only NNRTI PDR and those with no 
PDR if on EFV-based ART, with poorer response observed only when both NRTI and NNRTI PDR were 
present [9].  
 
Our findings suggest that the combination of TDF/FTC in the presence of good adherence is potent enough to 
achieve short-term VS despite the presence of NNRTI PDR. TDF/FTC/EFV was found to be either equivalent 
or superior to its comparator arms in a study comparing four WHO recommended regimens [24]. This 
observation was attributed to higher potency of EFV compared to NVP and the longer intracellular half of FTC-
triphosphate [25] than 3TC-triphosphate [26] which could mean better forgiveness of FTC containing regimen 
with missed ART doses. These factors may explain our finding of little impact of only NNRTI PDR. 
Some studies with small sample size have shown no association between PDR and virological outcomes [10-
13]. 
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Our PDR prevalence figures are similar to that of a recent study performed across all the South African 
provinces [27]. The high proportion of NNRTI resistance in this survey likely reflects the exposure of the 
population to NNRTI-based ART following the roll-out of the national HIV treatment programs. However, 
NRTI mutations, such as M184V which was present in our study, were unlikely to have been transmitted 
because of their fitness cost to the virus. Therefore, the presence of dual class NRTI/NNRTI mutations in our 
study may suggest previous ART exposure in patients who did not report it, as suggested in previous studies 
[27, 28]. Moreover, the use of NGS to detect minority variants at ART initiation could be clinically relevant, as 
poorer VS was observed in participants with NRTI/NNRTI detected at the 5% threshold.  
 
Our study has a few limitations. About 15% of participants had VL<1,000 copies/mL at entry, hence did not 
have virus sequenced. If this was due to undisclosed prior ART, we could have underestimated the prevalence 
of PDR in the population of HIV-positive individuals initiating or re-initiating ART. More females did not have 
sequences either because of low plasma VL or failure of sequencing. However, as there was no difference in the 
prevalence of PDR between males and females amongst those sequenced, we do not believe this would have 
biased our estimates of PDR. A small proportion (9.0%) of individuals with missing follow-up VL could not be 
evaluated for virological response. These were younger and more likely to be male; characteristics associated 
with poorer VS in our cohort [29], hence we could have overestimated virological response in the studied 
sample. However, this is unlikely due to the small number of participants with missing VL. 
 
The NNRTI DR threshold for considering a change in the first-line ART in a public health approach in low- and 
middle-income countries was recently lowered from 15% to 10% by the WHO [30, 31], with dolutegravir 
(DTG)-based first-line ART poised to replace EFV [32, 33] because of its higher VS rates, shorter time to VS 
and fewer side-effects [34, 35]. The precise impact of NRTI PDR on response to 
tenofovir/lamivudine/dolutegravir remains to be seen, although NNRTI PDR alone will not compromise this 
regimen. Moreover, there are also limited data on the use of DTG in patients with tuberculosis [36] which is 
prevalent in SSA, and in pregnancy [37] with recent data from Botswana suggesting a higher frequency of 
neural tube birth defects in women who conceived on DTG [38]. Hence there would still be HIV-positive 
individuals whom an EFV-based ART may be more appropriate. 
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In conclusion, in the setting of a community trial involving a large study population initiating a FDC of 
TDF/FTC/EFV in HIV-positive individuals, we found no association between the presence of only NNRTI PDR 
and VS, however PDR to both NRTI and NNRTI was associated with longer time to VS.  Good ART adherence 
and the high potency of TDF/FTC/EFV may have compensated for the presence of only NNRTI PDR.  Studies 
with longer duration of follow-up in real life public ART programmes are warranted to properly quantify the 
effect of PDR on clinical outcomes in the African setting, as new first-line regimens are rolled out. 
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Table 1. Demographic and clinical characteristics of all participants assessed for pre-treatment drug resistance*. 
Characteristics of 
individuals with sequences 
Total  
N=1,148 (%) 
Individuals without 
pre-treatment HIV 
drug resistance 
n=1, 039(%) 
Individuals 
with pre-treatment 
HIV drug resistance 
n=109 (%) 
Age  (Years)     
Median age (IQR) 32.9 (25.6-45.2) 33.3 (25.8-45.8) 30.0 (25.0-36.4) 
16-29 463 (40.3) 409(39.4) 54 (49.5) 
30-39 298 (26.0) 267 (25.7) 31 (28.4) 
40-49 178 (15.5) 168 (16.2) 10 (9.2) 
>50 202 (17.6) 189 (18.2) 13 (11.9) 
Missing 7 (0.6) 6 (0.6) 1 (0.9) 
Sex     
Female 807 (70.3) 729 (70.2) 78 (71.6) 
Male 341 (29.7) 310 (29.8) 31 (28.4) 
CD4 at presentation *     
Median (IQR) cells/mm
3
 404 (261-559) 405 (261-559) 383 (263-533) 
<350 448 (39.0) 404 (38.9) 44 (40.4) 
350-500 299 (26.1) 270 (26.0) 29 (26.6) 
>500 379 (33.0) 348 (33.5) 31 (28.4) 
Missing 22 (1.9) 17 (1.6) 5 (4.6) 
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Characteristics of 
individuals with sequences 
Total  
N=1,148 (%) 
Individuals without 
pre-treatment HIV 
drug resistance 
n=1, 039(%) 
Individuals 
with pre-treatment 
HIV drug resistance 
n=109 (%) 
Viral load* copies/mL    
Median (Log10)  4.5 (3.9-5.2) 4.5 (3.9-5.2) 4.6 (4.1-5.1) 
<10,000 309 (26.9) 285 (27.4) 24 (22.0) 
10,000-100,000 478 (41.6) 429 (41.3) 49 (45.0) 
>100,000 356 (31.0) 320 (30.8) 36 (33.0) 
Missing 5 (0.4) 5 (0.5) 0 (0.0) 
Education      
Primary or less 483 (42.1) 432 (41.6) 51 (42.5) 
Some secondary 427 (37.2) 385 (37.1) 47 (39.2) 
Secondary or higher 234 (20.4) 218 (21.0) 22 (18.3) 
Missing 4 (0.4) 4 (0.3) 0 (0.0) 
Marital status                   
Never married 1,009 (87.9) 904 (87.0) 105 (96.3) 
Married 92 (8.0) 89 (8.6) 3 (2.8) 
Divorced/Separated 43 (3.8) 42 (4.0) 1 (0.9) 
Missing 4 (0.4) 4 (0.4) 0 (0.0) 
Employment    
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Characteristics of 
individuals with sequences 
Total  
N=1,148 (%) 
Individuals without 
pre-treatment HIV 
drug resistance 
n=1, 039(%) 
Individuals 
with pre-treatment 
HIV drug resistance 
n=109 (%) 
Employed 166 (14.5) 155 (14.9) 11 (10.1) 
Student 60 (5.2) 53 (5.1) 7 (6.4) 
Unemployed 917 (79.9) 826 (79.5) 91 (83.5) 
Missing 5 (0.4) 5 (0.5) 0 (0·0) 
Receiving government grants    
Yes 662 (57.7) 597 (57.5) 65 (59.6) 
No  473 (41.2) 429 (41.3) 44 (40.4) 
Missing 13 (1.1) 13 (1.3) 0 (0.0) 
*Pre-treatment drug resistance is defined by NGS only 
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Table 2: Baseline characteristics of individuals contributing to the analysis of virological suppression. 
 
 
 In analysis 
n=837 (%) 
Missing VL 
N=83(%) 
 P value 
Age at initiation  (Years)       
Median age (IQR)  34.3 (27.3, 46.5) 29.5 (23.5, 41.6)  0.02 
16-29  290 (34.6) 43 (51.8)   
30-39  246 (29.4) 15 (18.1)   
40-49  133 (15.9) 9 (10.8)   
>50  166 (19.8) 13 (15.7)   
Missing  2 (0.2) 3 (3.6)   
Sex      
Female  599 (71.6) 48 (57.8)  0.009 
Male  238 (28.4) 35 (42.2)   
CD4 at initiation       
Median (IQR) cells/mm
3
  348 (227, 480) 399 (235, 521)  0.630 
<=350  418 (49.9) 37 (44.6)   
350-500  230 (27.5) 20 (24.1)   
>500  182 (21.7) 22 (26.5)   
Missing  7 (0.8) 4 (4.8)   
Viral load copies/mL      
Median (Log copies/mL)  4.6 (4.0, 5.2) 4.6 (3.9, 5.2)  0.818 
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TDF=tenofovir, FTC=emtricitabine, EFV=efavirenz, 3TC=lamivudine, AZT=zidovudine, D4T=stavudine, IQR interquartile 
range 
 
 
 
 
<10000  200 (23.9) 22 (26.5)   
10000-100000  350 (41.8) 36 (43.3)   
>100000  285 (34.1) 25 (30.1)   
Missing  2 (0.2) 0 (0.0)   
Adherence (%)      
<95  126 (15.1) -   
≥95  699 (83.5) -   
Missing  12 (1.4) -   
ART regimen     0.001 
TDF+FTC+EFV  806 (96.3) 73 (88.0)   
TDF+3TC+EFV  6 (0.7) 2 (2.4)   
AZT+3TC+ EFV  18 (2.2) 3 (3.6)   
D4T+3TC+EFV  1 (0.1) -   
AZT+3TC+PI  1 (0.1) -   
Missing  5 (0.6) 5 (6.0)   
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy881/5130579 by Sussex U
niversity user on 25 O
ctober 2018
  27 
Table 3. Factors associated with virologic suppression in adults with PDR detected at the 20% 
threshold 
Characteristics Unadjusted 
hazard ratio  
(95% CI) 
P value Adjusted                     
hazard ratio                  
(95% CI) 
P value 
Pretreatment Drug Resistance  0.06  0.09 
No PDR  1  1  
Only NNRTI PDR  0.84 (0.64-1.11)  0.90 (0.68-1.18)  
Both NNRTI/NRTI PDR 0.42 (0.16-1.12)  0.41 (0.15-1.10)  
Age at initiation/5 years 1.02 (1.00-1.05) 0.11 1.03 (1.00-1.06) 0.06 
Sex    0.01  0.69 
Female 1  1  
Male 0.82 (0.70-0.96)  0.97 (0.82-1.14)  
CD4 at initiation/100 cells/mm
3
 1.06 (1.03-1.09) <0.001 1.03 (1.00-1.06) 0.10 
Viral load copies/mL   <0.001  <0.001 
≤10000 1  1  
10000-100000 0.74 (0.61-0.88)  0.75 (0.62-0.90)  
>100000 0.47 (0.38-0.56)  0.48 (0.39-0.59)  
VAS Adherence (%)   0.001  0.003 
<95 1  1  
≥95 1.40 (1.14-1.73)  1.37 (1.11-1.70)  
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Table 4. Factors associated with virologic suppression in adults with PDR detected at the 5% 
threshold 
Characteristics Unadjusted 
hazard ratio  
(95% CI) 
P value Adjusted                     
hazard ratio                  
(95% CI) 
P value 
Pretreatment Drug Resistance    0.02 
No PDR    1  
Only NNRTI PDR    1.05 (0.82-1.34)  
Both NNRTI/NRTI PDR   0.32 (0.12-0.86)  
Age at initiation/5 years 1.02 (1.00-1.05) 0.11 1.03 (1.00-1.06) 0.05 
Sex   0.01  0.70 
Female 1  1  
Male 0.82 (0.70-0.96)  0.97 (0.82-1.14)  
CD4 at initiation/100 cells/mm
3
 1.06 (1.03-1.09) <0.001 1.03 (1.00-1.06) 0.09 
Viral load copies/mL  <0.001  <0.001 
≤10000 1  1  
10000-100000 0.74 (0.61-0.88)  0.74 (0.61-0.89)  
>100000 0.47 (0.38-0.56)  0.47 (0.39-0.58)  
VAS Adherence (%)  0.001  0.003 
<95 1  1  
≥95 1.41 (1.14-1.73)  1.38 (1.11-1.70)  
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Figure 1. Cohort flow chart 
 
Figure 2. Prevalence of any pretreatment drug resistance and NNRTI resistance among 1,148 participants with 
NGS data detected at 5% and 20% detection thresholds. 
 
Figure 3. Kaplan Meier plot of the cumulative probability of VS since ART start:  stratified by class of  PDR at 
the 20% (3a) and 5% (3b) detection thresholds. 
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Figure 1 
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Figure 2 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy881/5130579 by Sussex U
niversity user on 25 O
ctober 2018
  34 
Figure 3 
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